Ocugen to Present at May 2024 Investor Conferences
May 10 2024 - 7:45AM
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies and vaccines, today
announced that Dr. Shankar Musunuri, Chairman, Chief Executive
Officer and Co-founder, Ocugen, will present at The Citizens JMP
Life Sciences Conference taking place at the New York Hilton
Midtown from May 13 – 14, 2024. Additionally, Dr. Huma Qamar, Chief
Medical Officer, Ocugen, will participate in a fireside chat at the
H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
on May 20, 2024.
Details of the presentations are as follows:
The Citizens JMP Life Sciences Conference
Location: New York Hilton Midtown
Date: Monday, May 13, 2024
Time: 9:30 – 9:55 a.m. ET
Live Webcast: Available on Citizens JMP’s event
website The H.C. Wainwright 2nd
Annual BioConnect Investor Conference
Location: NASDAQ, Room 2 – Central
Date: Monday, May 20, 2024
Time: 12:30 – 1:00 p.m. ET
Live Webcast: Available on H.C. Wainwright’s
event website
During the presentations and one-on-one meetings, Ocugen senior
executives will showcase the Company’s recent business and gene
therapy clinical development progress including the OCU400 Phase 3
liMeliGhT clinical trial currently underway. OCU400, a modifier
gene therapy, is the first gene therapy program to enter Phase 3
with a broad retinitis pigmentosa indication.
A replay of the Citizens JMP & H.C. Wainwright webcasts will
be available in the Events section of the Company’s
website.
About Ocugen, Inc.Ocugen, Inc. is a
biotechnology company focused on discovering, developing, and
commercializing novel gene and cell therapies, biologics, and
vaccines that improve health and offer hope for patients across the
globe. We are making an impact on patient’s lives through
courageous innovation—forging new scientific paths that harness our
unique intellectual and human capital. Our breakthrough modifier
gene therapy platform has the potential to treat multiple retinal
diseases with a single product, and we are advancing research in
infectious diseases to support public health and orthopedic
diseases to address unmet medical needs. Discover more
at www.ocugen.com and follow us
on X and LinkedIn.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995, including, but
not limited to, statements regarding qualitative assessments of
available data, potential benefits, expectations for ongoing
clinical trials, anticipated regulatory filings and anticipated
development timelines, which are subject to risks and
uncertainties. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should,” or other words that convey uncertainty
of future events or outcomes to identify these forward-looking
statements. Such statements are subject to numerous important
factors, risks, and uncertainties that may cause actual events or
results to differ materially from our current expectations,
including, but not limited to, the risks that preliminary, interim
and top-line clinical trial results may not be indicative of, and
may differ from, final clinical data; that unfavorable new clinical
trial data may emerge in ongoing clinical trials or through further
analyses of existing clinical trial data; that earlier non-clinical
and clinical data and testing of may not be predictive of the
results or success of later clinical trials; and that that clinical
trial data are subject to differing interpretations and
assessments, including by regulatory authorities. These and other
risks and uncertainties are more fully described in our periodic
filings with the Securities and Exchange Commission (SEC),
including the risk factors described in the section entitled “Risk
Factors” in the quarterly and annual reports that we file with the
SEC. Any forward-looking statements that we make in this press
release speak only as of the date of this press release. Except as
required by law, we assume no obligation to update forward-looking
statements contained in this press release whether as a result of
new information, future events, or otherwise, after the date of
this press release.
Contact:Tiffany HamiltonHead of
CommunicationsTiffany.Hamilton@ocugen.com
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Oct 2023 to Oct 2024